When destiny doesn't pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan.

Schulte, Brian C; Hwang, Caleb; Horvai, Andrew E; Olivier, Timothee

Schulte, Brian C; Hwang, Caleb; Horvai, Andrew E; Olivier, Timothee.

Afiliación

Schulte BC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Hwang C; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Horvai AE; School of Medicine, University of California San Francisco, San Francisco, California, USA.
Olivier T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.

Cancer ; 2024 Aug 25.

Article en En | MEDLINE | ID: mdl-39182174

Palabras clave

HER2targeted therapy; US Food and Drug Administration (FDA) approval; sarcoma; trastuzumab deruxtecan (TDXd)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google